Re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist Cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-80

Eur Urol. 2009 Feb;55(2):e36-7; author reply e38-9. doi: 10.1016/j.eururo.2008.08.005. Epub 2008 Aug 8.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Clinical Trials, Phase II as Topic
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Gonadotropin-Releasing Hormone / toxicity
  • Hormone Antagonists / therapeutic use*
  • Hormone Antagonists / toxicity
  • Humans
  • Male
  • Organ Size
  • Prostate / pathology
  • Prostatic Hyperplasia / drug therapy*
  • Prostatic Hyperplasia / pathology
  • Prostatic Hyperplasia / physiopathology
  • Stem Cells / pathology

Substances

  • Androgen Antagonists
  • Hormone Antagonists
  • Gonadotropin-Releasing Hormone
  • cetrorelix